Xiaoming Fei Selected Research

Bortezomib (Velcade)

1/2014

In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiaoming Fei Research Topics

Disease

6	Multiple Myeloma 04/2024 - 01/2014
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2023 - 01/2022
1	Neoplasms (Cancer) 04/2024
1	Philadelphia Chromosome 01/2023
1	Obesity 01/2016
1	Infections 01/2016
1	Leukemia 01/2016
1	Liver Diseases (Liver Disease) 01/2016
1	Hematologic Neoplasms (Hematological Malignancy) 01/2016

Drug/Important Bio-Agent (IBA)

6	Chimeric Antigen ReceptorsIBA 04/2024 - 10/2019
3	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 04/2024 - 10/2019
3	B-Cell Maturation AntigenIBA 04/2024 - 10/2019
1	AntigensIBA 04/2024
1	Single-Chain AntibodiesIBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2015
1	Bortezomib (Velcade)FDA Link 01/2014

Therapy/Procedure

1	Immunotherapy 04/2024
1	Therapeutics 01/2023
1	Drug Therapy (Chemotherapy) 01/2016